




## Supercharge Site Selection with Al Digital Twins of Every Research Site on the Planet



## **About Ryght:**

Ryght's generative AI platform rapidly analyzes trial protocols and instantly connects clients with high potential research sites anywhere in the world. Our technology streamlines site selection, accelerates activation, and gets our clients' studies enrolling patients much faster than traditional approaches. Character length: 255

## What we offer

Traditional site Selection methods are outdated, inefficient, and expensive. Sponsors and CROS are still relying on spreadsheets of disparate data to evaluate sites, and feasibility assessment is plagued by guesswork and communication delays.

How does Ryght improve this process? The answer comes down to "digital twins". This technology is basically a virtual replica of real-world entities that allow users to monitor, analyze, and predict the performance of the physical entity it represents.

Ryght's software creates virtual replicas of every clinical research site on earth, providing sponsors with powerful predictive capabilities to increase efficiency, reduce costs, and improve patient outcomes.

With platform features including Network Navigator, Site Feasibility, Trial Exchange, and more, Ryght AI is the perfect clinical trial companion.

Ryght, Inc.

www.ryght.ai | email@partnername.com | 123-456-7890 See our offer on the Microsoft Commercial Marketplace

## What our customers are saying

"Ryght Al's unique and powerful platform streamlines clinical trials from site selection to activation and enrollment, ultimately speeding up time to market for our biopharma clients.

 Derek Grimes, Executive Vice President and Global Head of Clinical Research, QPS